Get the Stockscreener App
19.44
1.72%
-0.34
Urogen Pharma Ltd stock is traded at $19.44, with a volume of 1.04M.
It is down -1.72% in the last 24 hours and up +14.62% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$19.78
Open:
$19.84
24h Volume:
1.04M
Relative Volume:
0.35
Market Cap:
$899.37M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-5.297
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
-1.37%
1M Performance:
+14.62%
6M Performance:
+92.86%
1Y Performance:
+34.53%
1-Day Range:
$19.41
$19.99
1-Week Range:
$18.65
$20.11
52-Week Range:
$3.42
$21.02
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
19.44 | 897.52M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Price Channel Expanding on UroGen Pharma Ltd.’s ChartJuly 2025 Catalysts & Safe Capital Growth Plans - classian.co.kr
UroGen Pharma stock initiated at Overweight by Piper Sandler on Zusduri potential - Investing.com Australia
Urogen Pharma shares fall 1.49% premarket after Piper Sandler initiates coverage with an Overweight rating. - AInvest
UroGen Pharma: Targeting Profits In 2027 (NASDAQ:URGN) - Seeking Alpha
Real Time Chart Alerts Flash Bullish on UroGen Pharma Ltd.Jobs Report & Weekly Watchlist for Hot Stocks - metrotimes.co.kr
Machine Learning Models Forecast UroGen Pharma Ltd. Uptick2025 Volatility Report & Real-Time Price Movement Reports - theviewers.co.kr
UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology - MSN
UroGen Pharma Ltd. Matches Institutional Buying FilterJuly 2025 WrapUp & Accurate Intraday Trade Tips - beatles.ru
UroGen (URGN) Q2 Revenue Rises 11% - AOL.com
Is UroGen Pharma Ltd. affected by consumer sentimentPortfolio Performance Report & Technical Buy Zone Confirmations - thegnnews.com
How UroGen Pharma Ltd. stock performs during market volatilityQuarterly Performance Summary & Technical Buy Zone Confirmations - beatles.ru
Why UroGen Pharma Ltd. stock attracts strong analyst attentionQuarterly Risk Review & Stock Timing and Entry Methods - sundaytimes.kr
UroGen Pharma Ltd. Trading Near Value Zone — Recovery AheadQuarterly Profit Summary & AI Optimized Trade Strategies - sundaytimes.kr
UroGen Pharma stock price target reiterated at $35 by TD Cowen - Investing.com India
UroGen Pharma CMO Schoenberg sells $176k in shares By Investing.com - Investing.com South Africa
Insider Sell: Mark Schoenberg Sells 10,000 Shares of UroGen Pharma Ltd (URGN) - GuruFocus
UroGen Pharma CMO Schoenberg sells $176k in shares - Investing.com India
UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call Transcript - Insider Monkey
UroGen Pharma price target lowered to $40 at H.C. Wainwright - Investing.com India
UroGen Pharma price target lowered to $40 at H.C. Wainwright By Investing.com - Investing.com Australia
URGN: HC Wainwright Lowers Price Target to $40.00, Maintains Buy Rating | URGN Stock News - GuruFocus
Can UroGen Pharma Ltd. disrupt its industryFastest Growing Stock Radar - newsyoung.net
The UroGen Pharma Ltd. (NASDAQ:URGN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
UroGen Pharma's Q2 2025 Earnings: A Catalyst for Valuation Re-Rating in Uro-Oncology? - AInvest
UroGen Pharma Q2 2025 Earnings Call Transcript - AInvest
UroGen Pharma Ltd. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:URGN) - Seeking Alpha
Oppenheimer Maintains Buy Rating on Urogen Pharma with $31 Price Target - AInvest
UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI - TipRanks
UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer - MSN
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $32 - 富途牛牛
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $31 - 富途牛牛
Guggenheim raises UroGen Pharma stock price target to $32 on Zusduri launch - Investing.com Nigeria
UroGen Pharma Q2 Earnings Call: FDA Approval, Revenue Growth, and Expanded Sales Force - AInvest
UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... - Yahoo Finance
UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA A - GuruFocus
UroGen Pharma Outpaces Forecasts With Revenue And FDA Nod - Finimize
Urogen Pharma Q2 2025 Earnings Call Transcript - MarketBeat
Health Care Stocks Slipped As Big Players Disappointed - Finimize
UroGen Pharma (URGN) Receives Consistent "Buy" Rating from D. Boral Capital | URGN Stock News - GuruFocus
Sector Update: Health Care - MarketScreener
UroGen Pharma Tops Revenue Forecasts With FDA Approval In Tow - Finimize
Earnings call transcript: UroGen Pharma Q2 2025 results show revenue growth - Investing.com
Earnings call transcript: UroGen Pharma Q2 2025 results show revenue growth By Investing.com - Investing.com South Africa
Urogen Pharma Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat - Investing.com
UroGen Pharma earnings missed by $0.22, revenue topped estimates - Investing.com Australia
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDUR - GuruFocus
Earnings Flash (URGN) UroGen Pharma Posts Q2 Net Loss $1.05 a Share, vs. FactSet Est of $0.83 Loss - MarketScreener
UroGen Pharma Ltd. SEC 10-Q Report - TradingView
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Urogen Pharma Ltd Stock (URGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smith Jason Drew | General Counsel |
Jul 28 '25 |
Sale |
19.14 |
7,522 |
143,971 |
41,492 |
| Schoenberg Mark | Chief Medical Officer |
Jul 28 '25 |
Sale |
19.14 |
5,149 |
98,552 |
158,229 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):